Teva Pharma's listed shares up after company lifts 2024 forecasts
** U.S.-listed shares TEVA.N of Israel-based Teva Pharmaceutical rise 4.5% to $17.2 premarket
** Company raises its FY forecasts as it benefits from strong demand for its cheaper generic medicines and branded treatment for Huntington's disease (HD)
** TEVA is banking on its branded medicine trio — Austedo for treating HD, Ajovy for migraine and recently launched Uzedy for schizophrenia — to drive future growth
** "Impressive Q2 and guidance raise to lift shares into catalyst rich second-half" - brokerage Jefferies
** Company raises Austedo annual revenue forecast by $100 mln to about $1.6 bln
** Sees FY revenue in the range of $16-$16.4 bln, up from its previous range of $15.7-$16.3 bln
** Raises lower end of its 2024 per share profit forecast to $2.30 from $2.20, while maintaining the higher end of the range at $2.50
** As of last close, Teva's U.S.-listed shares up 57.2% YTD
Reporting by Pratik Jain in Bengaluru
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
